e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 99.60K | 98.10K | 101.30K | 97.70K | 108.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.60K | 98.10K | 101.30K | 97.70K | 108.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 99.60K | 98.10K | 101.30K | 97.70K | 108.50K |
| SG&A Expenses | 1.30M | 1.28M | 1.14M | 1.10M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.40M | 4.34M | 4.52M | 4.36M | 3.54M |
| Operating Income | -4.30M | -4.24M | -4.41M | -4.26M | -3.43M |
| Income Before Tax | -4.07M | -4.01M | -4.20M | -4.05M | -3.17M |
| Income Tax Expenses | -553.30K | -545.20K | -656.70K | -633.50K | -475.70K |
| Earnings from Continuing Operations | -3.51M | -3.46M | -3.54M | -3.42M | -2.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.51M | -3.46M | -3.54M | -3.42M | -2.69M |
| EBIT | -4.30M | -4.24M | -4.41M | -4.26M | -3.43M |
| EBITDA | -4.28M | -4.17M | -4.24M | -4.09M | -3.41M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 591.97M | 591.97M | 576.70M | 576.70M | 559.56M |
| Average Diluted Shares Outstanding | 591.97M | 591.97M | 576.70M | 576.70M | 559.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |